Overview

Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Treatments:
Immunoglobulin Fc Fragments
T0001